OncoMatch/Clinical Trials/NCT05775159

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Is NCT05775159 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for hepatocellular carcinoma.

Phase 2RecruitingAstraZenecaNCT05775159Data as of May 2026

Treatment: Volrustomig · Bevacizumab · Lenvatinib · Rilvegostomig · Gemcitabine · Cisplatin — GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Cholangiocarcinoma

Prior therapy

Cannot have received:

Previous treatment in the present study.

Lab requirements

Blood counts

Adequate organ and bone marrow function.

Kidney function

Adequate organ and bone marrow function.

Liver function

Adequate organ and bone marrow function.

Adequate organ and bone marrow function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Research Site · Birmingham, Alabama
Research Site · Costa Mesa, California
Research Site · Los Angeles, California
Research Site · Orange, California
Research Site · Miami Beach, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify